Rocket Lab Ahead of Earnings: The $49 Billion Price Tag for a $600 Million Business

Rocket Lab (NASDAQ: RKLB) reports second-quarter results after the bell on August 10. The stock has spent the last week acting like it already won — surging 27.5% in five days, 85% over the trailing year, sitting at $82.83 today. The market cap sits at nearly $49.5 billion.

The company generated $601.8 million in annual revenue and lost money doing it. I must admit that the disconnect is the kind that makes you pause and ask what the market is actually pricing in.

The Iridium Dream Is Already Baked In

The answer is in the headline that followed Rocket Lab out of Q1 earnings and into the summer: the $8 billion acquisition of Iridium Communications, announced June 29. The deal would add Iridium's operational LEO (low Earth orbit) constellation, 2.55 million subscribers, and roughly $872 million in annual revenue. That transforms Rocket Lab from a launch startup into a vertically integrated space operator with an existing cash-generating network.

The problem is that the deal is expected to close in mid-2027. It still needs stockholder approval and regulatory clearance. And none of that revenue, none of Iridium's $495 million in annual OEBITDA (operating earnings before interest, taxes, depreciation, and amortization), belongs to Rocket Lab yet.

Yet the stock's valuation treats it as if the ink is dry. At 72.9 times trailing sales on a standalone basis, RKLB is trading at roughly three times the revenue multiple you'd assign to the combined entity even after the deal closes. The market isn't just pricing in Iridium — it's pricing in Iridium plus flawless integration plus Neutron succeeding plus every government contract converting. That's arguably a doomsday narrative on the flip side: it assumes nothing goes wrong for the next 18 months.

The Standalone Business Doesn't Support This Valuation

Let's look at what Rocket Lab actually is right now, without the Iridium overlay. Q1 2026 revenue was $200.3 million, up 63.5% year over year. That's impressive growth. Gross margin hit a record 38.2% on a GAAP basis. The backlog is a record $2.2 billion.

But the operating margin is minus 33.2%. Free cash flow over the trailing twelve months is negative $316.3 million — a 46.5% cash burn rate against revenue. The company burns more than half a dollar in cash for every dollar of sales. ROIC (return on invested capital, a measure of how efficiently a company generates returns from its capital base) is minus 12.5%. This is a high-growth infrastructure build, not a profit engine.

Growth is accelerating — gross profit grew 95.3% year over year in the trailing period — but the path to profitability without Iridium remains years away. The forward P/E is negative, because the consensus still expects EPS losses into 2026. The Q2 forecast EPS of $0.09 that some services are citing doesn't match the earnings estimate data, which shows consensus expecting a loss of roughly minus $0.06 per share for Q2 2026. Even if the company hits the optimistic end of its guidance, it's not printing profits at scale.

The core thesis here is clear: Rocket Lab is a compelling growth story with real execution, growing revenue at 45.8% year over year with expanding margins and a record backlog. But a $49.5 billion market cap for a business that generates roughly $150 million per quarter and loses money on every single one of them requires a lot of future success to justify. The Iridium deal is the only thing bridging that gap — and the deal isn't done.

Neutron: Promise Without a Launch

Neutron, Rocket Lab's medium-lift reusable rocket, is the second pillar of the long-term thesis. Five dedicated Neutron launches were booked in Q1 alone, and the company has a contracted manifest exceeding 70 missions. The Archimedes engine qualification is progressing, and the company holds a U.S. government launch approval that expires in January 2027.

Neutron's first launch is targeted for the fourth quarter of 2026. That means Rocket Lab has roughly four months to execute a maiden flight on an unproven vehicle — one that the company itself has already slipped into mid-2026 from an earlier date. If Neutron launches cleanly, the medium-lift market opens up and the backlog starts converting into revenue at a much larger scale. If it fails or slips further, the growth timeline extends and the current valuation becomes even harder to defend.

Neutron is a real catalyst, not vaporware. But a rocket that hasn't flown yet is not a reason to assign a $49.5 billion value today.

What Earnings Could Change

Q2 2026 revenue guidance was $225 million to $240 million, with GAAP gross margin expected at 33% to 35%. Consensus estimates are roughly in line at $231.6 million. On the surface, the quarter doesn't need to do much — hitting the middle of guidance would confirm the growth trajectory without dramatically rewriting the outlook.

What would move the stock is forward commentary. An update pushing Iridium closer to closure, or a Neutron timeline that tightens to late 2026 with confidence, could sustain the rally. Conversely, any sign of Iridium regulatory friction, a Neutron slip into 2027, or guidance that falls short of the current range would expose how much of the current price is built on assumptions rather than executed results.

AInvest's aggregate signal labels the stock a Buy. The sell-side is broadly supportive. But consensus enthusiasm is exactly what makes this setup worth pausing on — when everyone is pointing in the same direction and the price has moved 85% in a year, the risk/reward for new entries shifts.

Price Action and Positioning

Technically, the stock is trading below its 50-day moving average of $90.55, despite sitting above the 200-day average of $77.98. The MACD is negative at minus 3.66, and the RSI sits at 56.2 — neutral territory, not overheated. The recent 27.5% five-day surge was sharp but the stock opened at $78.80 today, suggesting the rally hasn't found a sustainable base above $90.

Volume is heavy at 24.2 million shares with a turnover of $1.97 billion, reflecting active participation. But the fact that the stock has pulled back from its 52-week high of $151 and is trading below its 50-day MA tells you the momentum hasn't convinced enough buyers to hold higher levels.

Independent analyst fair value estimates, such as SimplyWallSt's recent revision to roughly $66.70, sit well below the current $82.83 price. That's not a sell signal by itself, but it does underscore how far the market is trading ahead of what fundamentals alone would suggest.

The Verdict: Patience Over Chasing

Rocket Lab is a real company with real growth, real contracts, and a credible path to becoming a dominant space infrastructure player. The Iridium acquisition, if it closes, is genuinely transformative — adding $872 million in revenue and $495 million in OEBITDA from a business with 57% margins. The Neutron program is on track. The backlog is record.

But the stock price has already priced in a best-case scenario for all three of those vectors. A $49.5 billion market cap for a standalone business burning $316 million in free cash flow requires the Iridium deal to close smoothly, Neutron to launch successfully, and execution to remain flawless through 2027. The market hasn't left room for anything to go sideways.

I don't think investors need to chase this one. The thesis is solid, but the entry point at current levels carries asymmetric downside — a slip on Neutron, a delay on Iridium, or a broader risk-off rotation could compress the multiple sharply from here. The better risk/reward is likely on a pullback toward the $65 to $70 range, where the Iridium thesis starts looking like a catalyst again rather than a given.

For existing holders, there's no reason to panic-sell. The growth trajectory remains intact and the Iridium deal is the single most accretive transaction in recent space history. But adding at these levels? That's where the discipline test comes in.

I would reassess the setup if Q2 earnings beat guidance meaningfully, if Neutron gets a firm flight date within weeks, or if Iridium moves materially closer to closing. Until then, the patient approach is the smarter one. Don't let the 85% rally convince you that the best move is to jump on the tail end of it.